Intech Investment Management LLC Raises Stock Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• Intech Investment Management LLC increased its stake in Halozyme Therapeutics by 9.9%, now owning 153,199 shares valued at approximately $9.8 million.
• Wall Street analysts have varied opinions on Halozyme, with one reducing its rating to "buy" while others have boosted price targets, showing mixed outlooks for the stock.
• Halozyme's recent earnings report showed a significant revenue increase of 40.8% year-over-year, reporting $325.72 million surpassing expectations.

Intech Investment Management LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 9.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 153,199 shares of the biopharmaceutical company's stock after acquiring an additional 13,789 shares during the quarter. Intech Investment Management LLC owned 0.12% of Halozyme Therapeutics worth $9,776,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Baird Financial Group Inc. boosted its position in Halozyme Therapeutics by 2.0% during the fourth quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company's stock worth $532,000 after purchasing an additional 221 shares in the last quarter. Captrust Financial Advisors boosted its position in shares of Halozyme Therapeutics by 24.3% in the 4th quarter. Captrust Financial Advisors now owns 29,862 shares of the biopharmaceutical company's stock worth $1,428,000 after buying an additional 5,829 shares in the last quarter. Gotham Asset Management LLC grew its stake in Halozyme Therapeutics by 9.7% in the 4th quarter. Gotham Asset Management LLC now owns 47,440 shares of the biopharmaceutical company's stock valued at $2,268,000 after acquiring an additional 4,178 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Halozyme Therapeutics by 28.8% during the 4th quarter. Janus Henderson Group PLC now owns 702,085 shares of the biopharmaceutical company's stock valued at $33,566,000 after acquiring an additional 156,912 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Halozyme Therapeutics by 4.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,087 shares of the biopharmaceutical company's stock worth $4,117,000 after acquiring an additional 3,874 shares during the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on HALO shares. Wall Street Zen lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. JMP Securities increased their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a report on Wednesday, August 6th. The Goldman Sachs Group assumed coverage on Halozyme Therapeutics in a report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price target for the company. Zacks Research raised Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. boosted their target price on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $67.11.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $75.80 on Thursday. The stock has a fifty day moving average price of $64.18 and a 200 day moving average price of $60.19. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $76.34. The firm has a market capitalization of $8.87 billion, a P/E ratio of 17.35, a PEG ratio of 0.42 and a beta of 1.19. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company had revenue of $325.72 million during the quarter, compared to analysts' expectations of $282.66 million. During the same quarter in the previous year, the business earned $0.91 EPS. The firm's revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the transaction, the chief executive officer owned 733,719 shares of the company's stock, valued at $46,598,493.69. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bernadette Connaughton sold 4,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the completion of the transaction, the director owned 46,952 shares in the company, valued at approximately $3,459,423.36. This trade represents a 7.85% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 104,000 shares of company stock valued at $6,316,120 in the last ninety days. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.